Dabrafenib monotherapy in BRAF+ non-small cell lung cancer - our experience.
Klin Onkol
; 33(6): 458-462, 2020.
Article
en En
| MEDLINE
| ID: mdl-33685196
ABSTRACT
BACKGROUND:
Activating BRAF mutations result in constitutive activation of the MAP kinase signaling cascade, stimulating cell proliferation. BRAF mutations are typical for malignant melanoma, but occur less frequently in other tumors, including in 1-2% cases of non-small cell lung cancer (NSCLC) [1,2]. CASE We present two case reports of BRAF+ NSCLC patients, treated with 3rd line dabrafenib monotherapy on our department, and also brief review of available information about dabrafenib and its use in monotherapy of BRAF+ NSCLC.CONCLUSION:
Monotherapy with BRAF inhibitors presents a viable alternative for BRAF+ NSCLC patients, incapable of combined therapy with trametinib. The lack of proper indication and reimbursement for NSCLC cases remains a problem, and individual treatment approval is required.Palabras clave
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Oximas
/
Carcinoma de Pulmón de Células no Pequeñas
/
Proteínas Proto-Oncogénicas B-raf
/
Inhibidores de Proteínas Quinasas
/
Imidazoles
/
Neoplasias Pulmonares
/
Antineoplásicos
Límite:
Humans
Idioma:
En
Revista:
Klin Onkol
Asunto de la revista:
NEOPLASIAS
Año:
2020
Tipo del documento:
Article